Milestone Pharmaceuticals Inc. Earnings Recaps
Q2 2026
Aug 14, 2026
Shares declined 15.7% following the quarter as investors reacted negatively to persistent low market access, with only 25% commercial insurance coverage during Q2 limiting growth potential despite early launch progress.
Key takeaways
- Total prescriptions grew to over 1,200 in Q2, up from around 300 in Q1, totaling more than 1,500 for the first half of 2026.
- Unique prescribers increased to over 600 in Q2 from about 200 in Q1, with over 800 total in the first half.
- Patient count receiving CARDAMYST rose to over 1,000 in Q2 compared to nearly 300 in Q1, totaling more than 1,300 in H1.
- Commercial formulary coverage remained stagnant at ~25% during Q2, only recently improving to over 50% in July/August, after the reported quarter.
- Phase III trial for AFib-RVR initiation underway, targeting a larger patient population with symptomatic atrial fibrillation requiring new self-administered treatments.
Q1 2026
May 14, 2026
Shares fell 9.5% following the quarter as investors reacted negatively to cautious early sales performance and a lack of clear near-term revenue acceleration despite a successful product launch and broad coverage progress.
Key takeaways
- CARDAMYST launched quickly after FDA approval in December 2025 and became available nationwide by end of January 2026.
- Approximately 600 total prescriptions were recorded through April, with steady month-over-month growth but still limited penetration.
- Over 400 unique prescribers and about 560 unique patients indicated initial broad physician interest, yet script volume remains modest.
- Early coverage includes 25% of commercially insured patients, anchored by Express Scripts formulary inclusion.
- Management highlights positive patient and provider feedback but does not provide explicit revenue or profit guidance, suggesting cautious outlook.